Abstract
Since the discovery of the lysophospholipid-sensitive receptor GPR55, hopes have been raised that targeting this G protein-coupled receptor (GPCR) may represent a novel approach for the treatment of metabolic disorders. We discuss conflicting evidence surrounding GPR55 physiology and highlight its potential as a novel target for the treatment of obesity and diabetes.
Original language | English |
---|---|
Pages (from-to) | 606-608 |
Number of pages | 3 |
Journal | Trends in Endocrinology and Metabolism |
Volume | 27 |
Issue number | 9 |
DOIs | |
Publication status | Published - 21 May 2016 |